Computing with evidence. Part II: An evidential approach to predicting metabolic drug-drug interactions

Journal of Biomedical Informatics

Volumn 42, Issue 6, 2009, Pages 990-1003

  Boyce, Richard ^a   Collins, Carol ^b   Horn, John ^b   Kalet, Ira ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug safety; Drug drug interactions; Evidence modeling; Evidentialism; HMG CoA reductase inhibitors; Knowledge representation; Statins

Indexed keywords

DRUG SAFETY; DRUG-DRUG INTERACTIONS; EVIDENCE MODELING; EVIDENTIALISM; HMG-COA REDUCTASE INHIBITORS; STATINS;

EXPERIMENTS; KNOWLEDGE REPRESENTATION; METABOLISM;

DRUG INTERACTIONS;

ALPRAZOLAM; ATORVASTATIN; CLARITHROMYCIN; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; NEFAZODONE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIAZOLAM;

ARTICLE; DRUG INTERACTION; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; KNOWLEDGE BASE; MEDICAL INFORMATICS; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

ALGORITHMS; AREA UNDER CURVE; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICAL INFORMATICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS;

EID: 70350571681     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2009.05.010     Document Type: Article

References (64)

1. Boyce R., Collins C., Horn J., and Kalet I. Modeling drug mechanism knowledge using evidence and truth maintenance. IEEE Trans Inform Technol Biomed 11 4 (2007) 386-397
2. Boyce R., Collins C., Horn J., and Kalet I. Computing with evidence part I: a drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform 42 6 (2009) 979-989
3. Horn J., Hansten P., and Chan L. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41 4 (2007) 674-680
4. R Development Core Team. R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria; 2006. ISBN 3-900051-07-0. Available from: http://www.R-project.org.
5. Falissard B. psy: Various procedures used in psychometry. R package version 0.7; 2007.
6. Shi J., Chapel S., Montay G., Hardy P., Barrett J.S., Sica D., et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 43 3 (2005) 123-133
7. Abbot. pce (erythromycin) tablet. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 03/03/2008.
8. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., and Schneck D.W. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59 1 (2003) 51-56
9. Novartis Pharmaceuticals Corporation. lescol (fluvastatin sodium) capsule; lescol XL (fluvastatin sodium) tablet, extended release. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 07/02/2008.
10. Kivisto K.T., Kantola T., and Neuvonen P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46 1 (1998) 49-53
11. Astrazeneca. crestor (Rosuvastatin calcium) tablet, film coated for oral use. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 04/17/2008.
12. Black D.J., Kunze K.L., Wienkers L.C., Gidal B.E., Seaton T.L., McDonnell N.D., et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24 4 (1996) 422-428
13. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., and Cantarini M.V. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58 8 (2002) 527-531
14. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., and Cantarini M.V. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73 4 (2003) 322-329
15. Rodrigues A.D., Roberts E.M., Mulford D.J., Yao Y., and Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25 5 (1997) 623-630
16. Squibb B-M. Pravachol (pravastatin sodium) tablet. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 03/19/2009.
17. Greenblatt D.J., von Moltke L.L., Harmatz J.S., Counihan M., Graf J.A., Durol A.L., et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 64 3 (1998) 278-285
18. Zimmermann T., Yeates R.A., Laufen H., Scharpf F., Leitold M., and Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 46 2 (1996) 213-217
19. Ohno Y., Hisaka A., and Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46 8 (2007) 681-696
20. Internal Authorship. FDA guideline: drug interaction studies-study design, data analysis, and implications for dosing and labeling; 2006. Available from: http://www.fda.gov/Cber/gdlns/interactstud.htm. Last accessed 09/25/2006.
21. van de Waterbeemd H., and Gifford E. ADMET in silico modeling: towards prediction paradise?. Nat Rev Drug Discov 2 3 (2003) 192-204
22. Yamashita F., and Hashida M. In silico approaches for predicting ADME properties of drugs. Drug Metab Phamacokin 19 5 (2004) 327-338
23. Obach R.S., Walsky R.L., Venkatakrishnan K., Houston J.B., and Tremaine L. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78 (2005) 582-592
24. Bonnabry P., Sievering J., Leemann T., and Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 40 9 (2001) 631-640
25. Zvada S.P., Chagwedera T.E., Chigwanda R., and Masimirembwa C.M. An experimental pharmacokinetic computer program to predict potential drug-drug interactions. Open Drug Metab J 3 (2009) 8-16
26. Klein T., Chang J., Cho M., Easton K., Fergerson R., Hewett M., et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogen J 1 (2001) 167-170
27. Karp P, Paley S, Krieger C, Zhang P. An evidence ontology for use in pathway/genome databases. In: Pacific symposium on biocomputing 2004; 2004. p. 190-201.
28. Tentori K., Crupi V., Bonini N., and Osherson D. Comparison of confirmation measures. Cognition 103 1 (2007) 107-119
29. Yasui N., Otani K., Kaneko S., Ohkubo T., Osanai T., Sugawara K., et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59 5 (1996) 514-519
30. Yasui N., Kondo T., Otani K., Furukori H., Kaneko S., Ohkubo T., et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 139 3 (1998) 269-273
31. Greenblatt D.J., Wright C.E., von Moltke L.L., Harmatz J.S., Ehrenberg B.L., Harrel L.M., et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64 3 (1998) 237-247
32. Schmider J., Brockmoller J., Arold G., Bauer S., and Roots I. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 9 6 (1999) 725-734
33. DeVane C.L., Donovan J.L., Liston H.L., Markowitz J.S., Cheng K.T., Risch S.C., et al. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol 24 1 (2004) 4-10
34. Greene D.S., Salazar D.E., Dockens R.C., Kroboth P., and Barbhaiya R.H. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15 6 (1995) 399-408
35. Siedlik P.H., Olson S.C., Yang B.B., and Stern R.H. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 39 5 (1999) 501-504
36. Teva, nefazodone hydrochloride (Nefazodone Hydrochloride) tablet. FDA-approved drug product labeling; 2006. Last accessed on DailyMed 04/21/2009.
37. Amsden G.W., Kuye O., and Wei G.C. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 42 4 (2002) 444-449
38. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94 9 (2004) 1140-1146
39. Abbott. Biaxin filmtab (clarithromycin) tablet, film coated. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 05/29/2008.
40. Azie N.E., Brater D.C., Becker P.A., Jones D.R., and Hall S.D. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64 4 (1998) 369-377
41. Biovail. cardizem (diltiazem hydrochloride) tablet, coated. FDA-approved drug product labeling; 2006. Last accessed on DailyMed 04/21/2009.
42. Backman J.T., Olkkola K.T., Aranko K., Himberg J.J., and Neuvonen P.J. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37 3 (1994) 221-225
43. Mousa O., Brater D.C., Sunblad K.J., and Hall S.D. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 67 3 (2000) 267-274
44. Varhe A., Olkkola K.T., and Neuvonen P.J. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 59 4 (1996) 369-375
45. Kantola T., Kivisto K.T., and Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64 2 (1998) 177-182
46. Ahonen J., Olkkola K.T., and Neuvonen P.J. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 51 5 (1997) 415-419
47. Kantola T., Backman J.T., Niemi M., Kivisto K.T., and Neuvonen P.J. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 56 3 (2000) 225-229
48. Mazzu A.L., Lasseter K.C., Shamblen E.C., Agarwal V., Lettieri J., and Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68 4 (2000) 391-400
49. Janssen. sporanox (itraconazole) capsule. FDA-approved drug product labeling; 2008. Last accessed on DailyMed 05/16/2008.
50. Chung E., Nafziger A.N., Kazierad D.J., and Bertino J.S.J. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79 4 (2006) 350-361
51. Gorski J.C., Jones D.R., Haehner-Daniels B.D., Hamman M.A., O'Mara E.M.J., and Hall S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64 2 (1998) 133-143
52. Gurley B., Hubbard M.A., Williams D.K., Thaden J., Tong Y., Gentry W.B., et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46 2 (2006) 201-213
53. Olkkola K.T., Aranko K., Luurila H., Hiller A., Saarnivaara L., Himberg J.J., et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53 3 (1993) 298-305
54. Olkkola K.T., Ahonen J., and Neuvonen P.J. ;The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82 3 (1996) 511-516
55. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55 5 (1994) 481-485
56. Lam Y.W., Alfaro C.L., Ereshefsky L., and Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43 11 (2003) 1274-1282
57. Phillips J.P., Antal E.J., and Smith R.B. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 6 5 (1986) 297-299
58. Varhe A., Olkkola K.T., and Neuvonen P.J. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41 4 (1996) 319-323
59. Neuvonen P.J., Varhe A., and Olkkola K.T. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 60 3 (1996) 326-331
60. Varhe A., Olkkola K.T., and Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56 6 Pt. 1 (1994) 601-607
61. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Duan S.X., Harrel L.M., Cotreau-Bibbo M.M., et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276 2 (1996) 370-379
62. Barbhaiya R.H., Shukla U.A., Kroboth P.D., and Greene D.S. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15 5 (1995) 320-326
63. Gladding P., Pilmore H., and Edwards C. Potentially fatal interaction between diltiazem and statins. Ann Intern Med 140 8 (2004) W31
64. Shaukat A., Benekli M., Vladutiu G.D., Slack J.L., Wetzler M., and Baer M.R. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 37 7-8 (2003) 1032-1035